Allena Pharmaceuticals Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Allena Pharmaceuticals in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Allena Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALNA, but not buy additional shares or sell existing shares.
View analyst ratings for Allena Pharmaceuticals or view top-rated stocks.

3 Wall Street research analysts have issued 12 month price targets for Allena Pharmaceuticals' shares. Their ALNA stock forecasts range from $3.00 to $11.00. On average, they anticipate Allena Pharmaceuticals' stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 5,545.2% from the stock's current price.
View analysts' price targets for Allena Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Allena Pharmaceuticals' stock was trading at $0.5925 at the start of the year. Since then, ALNA shares have decreased by 79.1% and is now trading at $0.1240.
View the best growth stocks for 2022 here.

Allena Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for Allena Pharmaceuticals.

Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) posted its quarterly earnings results on Monday, May, 16th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.02.
View Allena Pharmaceuticals' earnings history.

1 employees have rated Allena Pharmaceuticals CEO Louis Brenner, M.D. on Glassdoor.com. Louis Brenner, M.D. has an approval rating of 100% among Allena Pharmaceuticals' employees. This puts Louis Brenner, M.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Allena Pharmaceuticals include Protalix BioTherapeutics (PLX), Protalix BioTherapeutics (PLX), Senti Biosciences (SNTI), MiNK Therapeutics (INKT), IN8bio (INAB), PharmaCyte Biotech (PMCB), OKYO Pharma (OKYO), Evaxion Biotech A/S (EVAX), AVROBIO (AVRO), Cognition Therapeutics (CGTX), Pluristem Therapeutics (PSTI), Xtant Medical (XTNT), AIM ImmunoTech (AIM), CASI Pharmaceuticals (CASI) and Entera Bio (ENTX).
View all of ALNA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Allena Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), VYNE Therapeutics (VYNE), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Acasti Pharma (ACST) and Miragen Therapeutics (MGEN).

(ALNA) raised $80 million in an initial public offering on Thursday, November 2nd 2017. The company issued 5,300,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Allena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNA."

Allena Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.88%) and Frazier Management LLC (1.14%). Company insiders that own Allena Pharmaceuticals stock include Edward Wholihan and Louis Md Brenner.
View institutional ownership trends for Allena Pharmaceuticals.

ALNA stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., and Frazier Management LLC. Company insiders that have sold Allena Pharmaceuticals company stock in the last two years include Edward Wholihan, and Louis Md Brenner.
View insider buying and selling activity for Allena Pharmaceuticals or view top insider-selling stocks.

Shares of ALNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALNA stock can currently be purchased for approximately $0.12.

Allena Pharmaceuticals (NASDAQ:ALNA) has a market capitalization of $13.36 million.

Allena Pharmaceuticals employs 35 workers across the globe.

Allena Pharmaceuticals' mailing address is ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462. The official website for Allena Pharmaceuticals is www.allenapharma.com. The company can be reached via phone at (617) 467-4577, via email at [email protected], or via fax at 617-916-1871.